RepliCel Announces 2014 Third Quarter Financial Results

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 26, 2014) - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (TSX VENTURE:RP) (OTCQB:REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2014. All amounts included in this news release are expressed in Canadian dollars unless otherwise indicated. The Company's financial statements and management report are available at www.sec.gov, www.sedar.com and at www.replicel.com.

Over the past 24 months, RepliCel has built out a portfolio of products assembled around a cohesive cell therapy platform positioned to launch several concurrent trials with relatively near-term clinical readouts, which it believes will address significant needs in attractively large markets.

Highlights of the third quarter 2014 and subsequent events include:

• Completed pre-clinical regulatory meetings with German authorities for Phase 1 aged and sun damaged skin program
  
  
• Submitted clinical trial application to Health Canada for Phase 1/2 chronic Achilles tendinosis program
  
  
• Appointment of R. Lee Buckler as Vice President, Business and Corporate Development
  
  
• Joined the Industry Consortium of the Centre for Commercialization of Regenerative Medicine
  
  
• Presented and held partnership meetings at:
  
  
  • Rodman & Renshaw Global Investment Conference (New York)
  • Alliance for Regenerative Medicine's Stem Cell Meeting on the Mesa (San Diego)
  • BioJapan (Yokohama)

"In the third quarter of 2014, we both finalized and initiated a number of projects which we believe positioned the company for a series of exciting quarters beginning fourth quarter 2014," said David Hall, RepliCel CEO and President. "Our scientific, manufacturing, clinical and regulatory teams worked tirelessly to finalize the data needed to pull together the first of three clinical trial applications to be submitted in rapid succession."